Connect with us

Technology

Crédit Mutuel Alliance Fédérale accelerates deployment of generative AI in collaboration with IBM

Published

on

STRASBOURG, France and ARMONK, N.Y., June 27, 2024 /PRNewswire/ — Crédit Mutuel Alliance Fédérale, a pioneer in the adoption of Artificial Intelligence (AI) since 2016, invests in cutting-edge technologies. Used every day by its 25,000 advisors, AI freed up nearly 1 million hours of administrative work in 2023 to enable them to continue to best serve their members and clients.

Operating as a sovereign technology bank, Crédit Mutuel Alliance Fédérale stands out for its ability to carry out almost all of this IT processing in its own datacenters — an approach underpinned by the historic collaboration established between the teams of Euro-Information, the mutualist group’s technology subsidiary, and IBM (NYSE: IBM).

To maintain its lead in artificial intelligence, Crédit Mutuel Alliance Fédérale and Euro-Information are expanding their long-term collaboration with IBM via its IBM watsonx platform — an AI and data platform designed to help businesses develop responsible AI — deployed on Credit Mutuel’s in-house computing infrastructure. This collaboration will make it possible to accelerate and industrialize the deployment of generative AI.

Crédit Mutuel Alliance Fédérale plans to rely on in-house developments and on watsonx to progressively deploy thirty-five AI use cases in Crédit Mutuel and CIC networks, with planned availability for the first set this summer. The mutualist group is also testing the InstructLab technique, jointly developed by IBM and Red Hat, to allow it to design models specific to its field of activity using its own data.

“For the past eight years, the success of our collaboration with IBM in artificial intelligence technologies has demonstrated the relevance of our strategy combining mutualist commitment and innovation. With watsonx, the Euro-Information and IBM teams gathered within the Cognitive Factory are working on the industrialization of 35 new use cases to enable our banking advisors to always offer the best possible services to our customers and members,” indicates Éric Petitgand, Chief Executive Officer of Crédit Mutuel Alliance Fédérale.

“Because banking is a technological business, it is essential to constantly innovate in order to master the technologies of the future. Our collaboration with IBM is all the more strategic as the InstructLab technique will enable us to adapt generative AI to our pioneering commitments to ethical and trustworthy AI that meets the specific needs of our company,” says Frantz Rublé, President of Euro-Information.

“We are delighted to expand our collaboration with Crédit Mutuel Alliance Fédérale. watsonx will allow them to bring cutting-edge generative AI capabilities to improve the customer experience,” adds Sébastian Krause, SVP IBM Corporation.

“Our strategic collaboration with the Crédit Mutuel Group and Euro-Information is thus further strengthened around three pillars: technological innovation, acceleration of transformation, and talent development,” concludes Jean-Philippe Desbiolles, IBM Managing Director for Crédit Mutuel Alliance Fédérale.

Generative AI for enhanced customer relations with the dedicated local advisor

Crédit Mutuel Alliance Fédérale has relied since its creation on technology to best serve its customers and members. In collaboration with IBM Consulting, Euro-Information’s Cognitive Factory has already massively deployed several cutting-edge artificial intelligence solutions, including for customer experience, risk management and compliance, support for account managers and document understanding.

Building on its know-how, Euro-Information will develop 35 AI use cases on an industrial scale, relying on in-house developments and on watsonx. Three initial generative AI solutions are expected to be deployed in the third quarter, enabling advisors to respond even more efficiently to the needs of their customers and members. In addition to MonIA, a broad catalog of AI-based services (document synthesis, transcription of appointments, etc.), they could benefit from templates for replying to customer emails, as well as an AI assistant providing personalized responses to help them with their assignments. A fourth pilot will support the Group’s IT development employees.

Managing the value chain for building ethical and trustworthy AI

Crédit Mutuel Alliance Fédérale, via the Chambre Syndicale et Interfédérale – its parliament made up of elected members and employees – has adopted a charter for trustworthy AI. This charter sets out commitments that govern the use of AI. IBM’s watsonx.governance will help Euro-Information implement them.

In this context, the governance of the mutualist group places AI at the service of human beings: elected representatives, employees, members and customers. It ensures strict respect for digital privacy. Bringing transparent and documented use of AI, it favors the most sober technological solutions and ensures that the principle of pooling banking and insurance offers is perpetuated to guarantee the interests of members and customers.

These collective choices are made possible because Crédit Mutuel Alliance Fédérale operates as a sovereign industrial bank. In this respect, almost all IT processing is carried out on its own datacenters located in France and Europe, using software over which it has full control.

Press Contacts

Crédit Mutuel Alliance Fédérale: Aziz Ridouan – +33 (0)6 01 10 31 69 – aziz.ridouan@creditmutuel.fr
IBM: Gaëlle Dussutour – +33 (0)6 74 98 26 92 – dusga@fr.ibm.com

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service.

Visit ibm.com for more information.

About Euro-Information

Euro-Information is the technology subsidiary of Crédit Mutuel. Euro-Information manages the IT systems of 16 federations of the Crédit Mutuel group as well as those of CIC and of all the financial, insurance, property, consumer credit, private banking, financing, telephony and technological subsidiaries.

With a headcount of almost 4 000, Euro-Information offers cutting-edge technology to employees and banking customers alike, backed up by a high level of security and personal data protection. Euro-Information has in-house expertise in all technologies and carries out the developments necessary for the entities of the Crédit Mutuel group.

For more information e-i.com

About Crédit Mutuel Alliance Fédérale

One of France’s leading bankinsurers, with 77,000 employees serving more than 31 million customers, Crédit Mutuel Alliance Fédérale’s more than 4,300 branches offer a diversified range of services to private individuals, local professionals and companies of all sizes.

Crédit Mutuel Alliance Fédérale, first French banking group to have adopted the status of mission-driven company, is made up of the following Crédit Mutuel federations: Centre Est Europe (Strasbourg), Sud-Est (Lyon), Île-de-France (Paris), Savoie-Mont Blanc (Annecy), Midi-Atlantique (Toulouse), Loire-Atlantique et Centre-Ouest (Nantes), Centre (Orléans), Normandie (Caen), Dauphiné-Vivarais (Valence), Méditerranéen (Marseille), Anjou (Angers), Massif Central (Clermont-Ferrand), Antilles-Guyane (Fort-de-France) and Nord Europe (Lille).

Crédit Mutuel Alliance Fédérale also includes Caisse Fédérale de Crédit Mutuel, Banque Fédérative du Crédit Mutuel (BFCM) and all its subsidiaries, in particular CIC, Euro-Information, Assurances du Crédit Mutuel (ACM), Targobank in Germany, Cofidis, Beobank in Belgium, Banque Européenne du Crédit Mutuel (BECM), Banque Transatlantique, Banque de Luxembourg, and Homiris.

Find more information at http://www.creditmutuelalliancefederale.fr/en/

Logo – https://mma.prnewswire.com/media/2319830/4785061/IBM_LOGO_1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/credit-mutuel-alliance-federale-accelerates-deployment-of-generative-ai-in-collaboration-with-ibm-302184025.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Enverus releases Investor Analytics: Refined, actionable financial insights at your fingertips

Published

on

By

New generative AI tool harnesses insights from earnings, investment power, oil and gas M&A, and what’s driving the energy transition

AUSTIN, Texas, April 25, 2025 /PRNewswire/ — Enverus, the most trusted energy-dedicated SaaS company that leverages generative AI across its solutions, announced it has added Investor Analytics to its suite of offerings. This cutting-edge solution stemming from Enverus’ flagship AI tool, Instant Analyst™, is designed to provide investors with a comprehensive view of key market dynamics. Investor Analytics delivers refined and actionable insights into financials, investor behavior, private equity trends and performance metrics, all vetted by Enverus experts.

This new solution, combined with other offerings like Enverus M&A Analytics for oil and gas deals or Energy Transition M&A, which provides guidance and analytics for navigating energy transition transactions, covers 30 asset types including established power generation assets, CCUS, hydrogen and emerging technologies. Together, these generative AI tools offer comprehensive M&A coverage and knowledge for a vast range of energy deal teams, executives and investors.

Investor Analytics empowers users with timely and actionable insights, enabling them to find answers faster, sharpen their competitive edge and navigate opportunities and risks with greater precision. Investor Analytics will be on full display at EVOLVE 2025, Enverus’ upcoming three-day conference held May 12-15, 2025, at the Hilton Americas in downtown Houston, where visionaries converge to shape the future of energy. EVOLVE will feature more than 65 sessions with 130 speakers focused on technology and energy innovation and exclusive insights from the Enverus Intelligence® Research team. This powerhouse symposium offers unmatched market insights, cutting-edge technological know-how and the chance to connect with industry leaders across the entire energy spectrum.

Continue reading our extended Investor Analytics announcement and EVOLVE 2025

About Enverus
Enverus is the most trusted energy-dedicated SaaS company, with a platform built to maximize value from generative AI, offering anytime, anywhere access to analytics and insights. These include benchmark cost and revenue data sourced from more than 95% of U.S. energy producers and more than 40,000 suppliers. Our platform, with intelligent connections, drives more efficient production and distribution, capital allocation, renewable energy development, investment and sourcing. Our experienced industry experts support our customers through thought leadership, consulting and technology innovations. We provide intelligence across the energy ecosystem: renewables, oil and gas, financial institutions, and power and utilities, with more than 7,700 customers in 50 countries. Learn more at Enverus.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enverus-releases-investor-analytics-refined-actionable-financial-insights-at-your-fingertips-302438614.html

SOURCE Enverus

Continue Reading

Technology

Goodwin Partners with Cincinnati Bengals to Power “Meet the Draft Picks” Event for Bengals Premium Suite Holders

Published

on

By

COLUMBUS, Ohio, April 25, 2025 /PRNewswire/ — Goodwin, an Ohio-based software company built for charter aviation brokers, is proud to announce its official sponsorship of the Cincinnati Bengals’ “Meet the Draft Picks” event for Bengals Premium Suite Holders, taking place this Saturday, April 26.

As a part of its broader partnership with the Bengals’ Suite Program, Goodwin is bringing its spirit of Ohio ingenuity and seamless connectivity to this exclusive event, where the Bengals Premium Suite Holders will get a first look at the Bengals’ 2nd and 3rd round draft picks.

The event timeline includes:

Player introductions and fan meet-and-greetsLive draft insights from Bengals broadcasters Dan Hoard and Dave LaphamBehind-the-scenes tours of the state-of-the-art Kettering Health Performance CenterPhoto ops with Who Dey and the Ben-GalsComplimentary beverages and hors d’oeuvresLive Day 3 NFL Draft coverage

“As a company born and built in Ohio, we’re thrilled to partner with a team that represents the heart of this community,” said Tolga Demirel, Co-Founder of Goodwin. “Our technology is designed to make every connection—from brokers to operators to aircraft—as smooth and intuitive as possible. When things just work, that’s Goodwin Generated.”

Goodwin’s platform is quickly becoming the go-to solution in the charter aviation space, offering a seamless booking and backend support for brokers and operators. By empowering aviation professionals with tools that work smarter, faster and more transparently, Goodwin is helping reshape what modern air travel looks like—starting right here in the Midwest.

The Bengals’ “Meet the Draft Picks” event is the perfect kickoff to a partnership grounded in performance, innovation and Ohio pride.

For more information about Goodwin and its mission, visit www.teamgoodwin.com

About Goodwin

Founded in 2022, Goodwin is headquartered in Ohio with technical talent across the U.S. The company is revolutionizing the charter aviation industry with innovative technology that streamlines charter operations. Goodwin acts solely in a B2B capacity, supporting brokers and operators in digitizing and elevating their workflows, ensuring charter aviation professionals can focus on building meaningful client relationships and scaling their businesses. For more information about how Goodwin is reshaping the charter landscape, please visit www.teamgoodwin.com or follow us on LinkedIn to stay updated.

Media Contact: Clara Armagast
clara@teamgoodwin.com
304-688-5179

View original content to download multimedia:https://www.prnewswire.com/news-releases/goodwin-partners-with-cincinnati-bengals-to-power-meet-the-draft-picks-event-for-bengals-premium-suite-holders-302438634.html

SOURCE Goodwin

Continue Reading

Technology

Precision for Medicine and PathAI Announce Strategic Collaboration to Advance AI-Powered Clinical Trial Services and Biospecimen Products

Published

on

By

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery

BOSTON and FREDERICK, Md., April 25, 2025 /PRNewswire/ — Precision for Medicine, a leading provider of next generation drug development research and services, and PathAI, a global leader in digital pathology, today announced a strategic collaboration to partner on developing novel AI-based technologies and to integrate PathAI’s advanced digital pathology and analysis capabilities across Precision for Medicine’s clinical trial and biospecimen operations.

The collaboration’s innovative tools will provide a level of integration and customization not available elsewhere.

This collaboration includes use of several PathAI technologies and establishes an agreement to offer novel tools and analytical services that address emerging needs in biomarker discovery, spatial biology, and tissue-based clinical research. Through this collaboration PathAI’s tools and services will help augment Precision for Medicine’s proprietary pipeline providing biopharma clients with access to imaging workflows offered through Precision for Medicine’s integrated laboratory and clinical trial services.

“Together, we’re deploying tools that add critical quality control steps to tumor biopsy workflows and apply machine-based learning and unsupervised algorithms early in the development cycle to help identify which biomarkers are most relevant for clinical efficacy,” said Darren Davis, PhD, Senior Vice President Global Digital Pathology, Genomics and Liquid Biopsy Solutions. “Precision for Medicine’s CLIA compliant laboratory enables precise patient stratification and accelerate decision-making in clinical trials, ultimately supporting success in areas of high unmet need.”

As part of the agreement, Precision for Medicine will deploy select tools from PathAI, including AISight®, a digital pathology image management system, and other AI-powered algorithms to enhance biospecimen and clinical trial services. These tools will enable the application of validated, algorithm-based quality control steps to biospecimen analysis, improving consistency and data reliability.

The collaboration will also support the use of PathAI’s leading AI capabilities leveraging best in class machine learning based models to enhance Precision for Medicine multi-modal datasets. The technology reduces large, complex biomarker panels to scalable, and actionable, biomarkers to help interpret complex tissue biology to complement translational research programs. Additionally, the companies will work together to analyze complex tissue biology empowering biopharma clients to understand and identify the right patients for the right therapies, faster.

“At PathAI, our mission is to harness the power of artificial intelligence to improve the accuracy, depth, and efficiency of pathology-driven insights,” said Andy Beck, MD, PhD, Co-founder and CEO of PathAI. “We are thrilled to collaborate with Precision for Medicine to help advance our mission and deliver differentiated value to our mutual customers.”

Precision’s collaboration with PathAI brings unique value to biopharma clients by combining these AI tools with proprietary wet lab infrastructure, centralized clinical trial operations, and scientific oversight. The innovative tools generated through this collaboration will only be available through Precision for Medicine’s services, providing a level of integration and customization not offered elsewhere in the industry.

“This collaboration enhances how we’re using our biospecimen business by enabling deeper, more informative analyses of the tissue samples we provide to our clients,” said Cullen Taylor, MD, Medical Director at Precision for Medicine. “We’re adding an entirely new layer of cellular-level insight on top of already well-annotated sequenced samples, going far beyond what traditional pathology assessments can offer. It’s a meaningful step forward in how we support biomarker discovery, enhancing datasets for diagnostic validation and therapeutic development.”

About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise, data sciences and advanced manufacturing solutions. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,500 people in 40 locations globally across North America, Europe and Asia-Pacific. For more information, visit precisionformedicine.com

Contact
Andie Lunkenheimer
andie.lunkenheimer@gcihealth.com

About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit pathai.com

Contact
Owen Blaschak
oblaschak@lifescicomms.com

Footnote

1AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK

View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-for-medicine-and-pathai-announce-strategic-collaboration-to-advance-ai-powered-clinical-trial-services-and-biospecimen-products-302438551.html

SOURCE PRECISION FOR MEDICINE

Continue Reading

Trending